

INDEX

Environmental Tobacco Smoke is abbreviated as ETS throughout this index.

ABSORPTION

- biological markers for ETS, 200-206
- biological markers of smoke absorption in smokers and nonsmokers, 181
- ETS vs. active smoking, comparison, 215-216
- nicotine, tobacco smoke exposure determination, 203-205

ACROLEIN

- measurement under realistic conditions (table), 148

ADOLESCENTS

- regulations in schools to prevent smoking initiation, 282

AEROSOLS

- mainstream smoke, particle size measurement during laboratory smoking, 182-183, 186
- monodisperse vs. polydisperse, affect on respiratory tract deposition, 181-182
- regional deposition in respiratory tract, smoke particle size as factor, 189, 191-192
- sidestream smoke, mass median diameter effect on deposition in respiratory tract, 187

AGE FACTORS

- respiratory effects of involuntary smoking in infants and children, 42-44

AIR POLLUTION

- (See also ENVIRONMENTAL TOBACCO SMOKE)
- hospital smoking policies, assessment of effect, 311

ALDEHYDES

- irritant in ETS, 229

AMMONIA

- irritant in ETS, 229

AROMATIC AMINES

- sidestream smoke levels higher than in mainstream smoke, 14

AROMATIC HYDROCARBONS

- measurement under realistic conditions (table), 149-150

ASTHMA

- (See also RESPIRATORY TRACT DISEASES)
- children, maternal smoking as risk factor, 55-58
- pulmonary function in adult asthmatics exposed to cigarette smoke, 63, 65

ATTITUDES

- public attitudes and social norms, cigarette consumption relationship, 321
- public knowledge and attitudes about smoking, assessment by surveys, 307
- public toward smoking, conclusions of 1986 report, 324
- review of impact of smoking restrictions, 319-320
- smokers on cessation or reduction, restrictions and social norms as factors, 305

BEHAVIOR, HUMAN

- (See also SMOKING CHARACTERISTICS; SMOKING HABIT)
- anticipated changes by smokers to workplace regulations, 312
- assessment of impact of smoking policies on smokers, 307

INDEX

BEHAVIOR, HUMAN—Contd.

- bans on smoking, effect on behavior of smokers, 16
- direct and indirect effects of smoking policies, 304
- hospital employees, smoking behavior before and after policy implementation, 315
- hospital patients and employees, current evidence of smoking policies, 308–309
- nonsmoking as normative behavior, reinforcement with smoking policies, 304
- reduction or cessation of smoking, indirect effect of smoking policies, 304–305
- research recommendations, effect of smoking restrictions, 322
- review of impact of smoking restrictions, 320–321
- smoking policy impact, evaluation, 306

BIOASSAY

- chemical assays for human exposure to cigarette tar components, 206, 217
- cotinine levels as measure of nicotine absorption, 205–206
- nicotine in blood for exposure determination, feasibility, 205

BIRTH WEIGHT

- maternal smoking as risk factor, 6

BLOOD

- cotinine level as marker for ETS exposure in nonsmokers, 36
- cotinine levels as measure of nicotine absorption in nonsmokers, 205–206
- cotinine levels in ETS-exposed nonsmokers vs. active smokers (table), 211–214
- nicotine and cotinine levels to quantify ETS exposure, 208
- nicotine levels in ETS-exposed nonsmokers vs. active smokers (table), 209–210
- nicotine levels in nonsmokers vs. smokers, 216
- white blood cell counts in smokers vs. nonsmokers, 244

BRAIN CANCER

- (See also CANCER)
- ETS exposure as risk factor, 102, 104

BREAST CANCER

- (See also CANCER)
- spousal smoking as risk factor, 102

BRONCHITIS

- (See also RESPIRATORY TRACT DISEASES)
- children, involuntary smoking relationship, longitudinal studies, 38, 42
- children of smokers, conclusions about risk, 106
- infants and children, parental smoking as risk factor, 10

CANCER

- (See also BRAIN CANCER; BREAST CANCER; CERVICAL CANCER; LUNG CANCER; RESPIRATORY TRACT CANCER)
- carcinogenesis, initiators and promoters in tobacco smoke, 28
- carcinogens in ETS as risk factors, 135
- children, parental smoking as risk factor for cancers other than lung cancer, 102–105
- ETS exposure risk, 102–104
- involuntary smoking relationship requires further investigation, 14
- smoking as major risk factor, 6

CARBON MONOXIDE

- acute toxicity in animals as factor in smoke carcinogenicity testing, 247
- biological marker for ETS absorption, 201–202
- ETS exposure measurement, lack of specificity as limitation, 202
- involuntary smoking exposure may be more constant than active smoking, 202
- lung deposition kinetics as factor in temporal variation in concentration, 201–202
- measurement under realistic conditions (table), 151–154
- sidestream smoke vs. mainstream smoke, 129

INDEX

CARBON MONOXIDE—Contd.

workplace level, contribution of tobacco smoke, 232

CARBOXYHEMOGLOBIN LEVELS

biological marker for carbon monoxide exposure, 202

CARCINOGENESIS

initiators and promoters of cancer in tobacco smoke, 28
tumor induction in animal tissues with cigarette smoke condensate, 249-250

CARCINOGENS

environmental vs. mainstream smoke, 134-135, 137
ETS vs. mainstream smoke in indoor environments (table), 136
human and animal, definition, 135, 137
mainstream and sidestream smoke, 23-24
sidestream and ETS, 251-252

CARDIOVASCULAR DISEASES

ETS exposure as factor not established, 10-11
involuntary smoking as risk factor, conclusions, 107-108
involuntary smoking relationship requires further investigation, 14
nonsmokers, prospective and case-control studies, 105-106

CASE-CONTROL STUDIES

(*See also* EPIDEMIOLOGICAL STUDIES)

cardiovascular disease risk, 105-106
lung cancer risk, 97-98
lung cancer risk in exposed nonsmokers, Hong Kong study, 80-81
lung cancer risk in spouses of smokers, Louisiana study, 79-80
lung cancer risk in wives of smokers, Greek study, 78-79
lung cancer risk relationship, Four Hospitals study, 84-86
lung cancer risk relationship, German study, 90
lung cancer risk relationship, Japanese study, 88-89
lung cancer risk relationship, Swedish study, 89-90

CASE-CONTROL STUDIES

lung cancer risk relationship, United Kingdom study, 86-88
respiratory disease risk in children, 43-44

CELLS

inflammatory cell number and function in smokers, inferences for involuntary smokers, 244-245
inflammatory, experimental models of cigarette smoke inhalation, 245-246
inflammatory, need to determine effect of ETS exposure, 252

CELLS, EPITHELIAL

chronic ETS exposure, inferred risk in nonsmokers, 240-241
ETS exposure effect, research needed, 252
hyperplasia, loss of cilia, nuclear atypia, smoking habit relationship, 239-240

CERVICAL CANCER

(*See also* CANCER)
spousal smoking as risk factor, 102

CESSATION OF SMOKING

public attitudes and smoking policies as indirect influences, 304-305
research recommendations on effect of smoking restrictions, 322
workplace programs as part of smoking control, 297
workplace programs, survey data, 294
workplace smokers motivation and success, smoking policies as factor, 313-315

CESSATION OF SMOKING, METHODS

workplace program, smoking policy implementation effect on participation, 314-315

CHEMICAL ANALYSIS

sidestream vs. mainstream smoke, 127

CHILDREN

asthma, maternal smoking as risk factor, 55-58
brain tumors, maternal smoking as factor, 104

INDEX

CHILDREN—Contd.

- bronchitis, involuntary smoking relationship, longitudinal studies, 38, 42
- cancer risk other than lung cancer, parental smoking as risk factor, 102-105
- cough, phlegm, and wheezing, parental smoking as risk factor, 44, 47-49
- ETS exposure, determinants, 12
- ETS exposure, reported irritation, 239
- health risks of ETS exposure, conclusions, 107
- health risks of involuntary smoking, summary and conclusions of 1986 report, 12-13
- leukemia, maternal smoking during pregnancy as factor, 103
- lung cancer risk, parental smoking as factor, 90-91
- lung function, information needed on relationship with ETS exposure, 32
- lung function, involuntary smoking risk relationship (table), 50-52
- lung function, maternal smoking relationship, 49, 53-54
- lung function, parental smoking as factor, 13, 107
- middle ear effusions and diseases, parental smoking risk relationship, 58-59
- respiratory diseases, involuntary smoking relationship (table), 39-41
- respiratory diseases, parental smoking as risk factor, 10, 13, 43-44
- respiratory function tests, maternal smoking as factor, 53
- respiratory symptoms in children of smokers, 13
- respiratory symptoms, relationship with involuntary smoke exposure (table), 45-46
- respiratory system effects of involuntary smoking, 37-59
- saliva cotinine concentrations, influence of parental smoking, 207-208

CIGARETTE EQUIVALENTS

- calculation of individual constituents needed to determine disease risk, 199-200
- involuntary smoking toxicity estimation, mathematical modeling, 198-200

CIGARETTE SMOKE

(See also ENVIRONMENTAL TOBACCO SMOKE; MAINSTREAM SMOKE; SIDESTREAM SMOKE; SMOKE STREAMS; TOBACCO SMOKE)

- aerosol, suspension of particles in a gaseous or vapor medium, 181
- animal models of carcinogenicity, 247-249
- carcinogenicity, condensate bioassay as alternative to smoke exposure, 249-250
- carcinogenicity demonstrated in animal models, 252
- carcinogenicity testing in animals, nicotine and carbon monoxide toxicity as factor, 247
- ETS in public places, major source, 128
- inflammatory cell function, experimental models of inhalation effect, 245-246
- particulate mass deposited in respiratory tract, 193, 198
- particulate phase constituents, sidestream to mainstream ratio (table), 130-131
- regional deposition in respiratory tract, particle size as factor, 189, 191-192
- total suspended particulates generated under laboratory conditions (table), 197
- toxic and carcinogenic agents in indoor environments (table), 136
- unfiltered cigarette, comparison of mainstream and sidestream smoke (table), 128
- vapor phase constituents, sidestream to mainstream ratio (table), 130-131

CIGARETTES

- nonfiltered, vapor and particulate phase smoke components (table), 130-131

INDEX

COMBUSTION TEMPERATURE

- mainstream and sidestream smoke, effect on composition, 24
- sidestream vs. mainstream smoke generation, effect on component levels, 128-129

COTININE

- biological marker for ETS absorption, 35-36, 200
- blood levels in nicotine-injected vs. smoke-exposed nonsmokers, 215-216
- body fluid level as marker for smoke exposure in nonsmokers, 8
- body fluid levels in nonsmokers as measure of nicotine absorption, 205
- body fluid levels in nonsmokers to establish lung cancer risk, 95
- body fluid levels increase with reported ETS exposure, 15, 217
- ETS exposure marker of choice in epidemiological studies, 217
- ETS exposure marker under real-life conditions, 207
- ETS exposure quantification, 208, 215
- nicotine absorption estimation, 205-206
- plasma, urine, saliva concentrations, correlation, 205
- plasma, urine, saliva levels in ETS-exposed nonsmokers vs. active smokers, 211-214
- urinary levels in ETS-exposed vs. nonexposed men, 207

COUGH

(*See also* RESPIRATORY SYMPTOMS)

- children of parents who smoke, relationship, 44, 47-49

EARS

- middle ear effusions in children of smokers, 58-59, 107

EMPHYSEMA

(*See also* RESPIRATORY TRACT DISEASES)

- nonsmokers vs. smokers, 246

ENVIRONMENTAL TOBACCO

SMOKE

(*See also* CIGARETTE SMOKE; INVOLUNTARY SMOKING; MAINSTREAM SMOKE; SIDESTREAM SMOKE; TOBACCO SMOKE)

- absorption of constituents by nonsmokers under experimental and natural exposure, 206-207
- active smoking dose-response relationships provide insight into risks, 26-28
- acute exposure, irritation effects, 229-239
- acute physiological response, experimental studies, 233-239
- air dilution effect on particle size and distribution, 134
- airways hyperresponsiveness and other factors in response, 28
- annoying and irritating effects of exposure, field and experimental studies, 231-239
- assessment techniques needed of recent and remote exposure, 14
- atmospheric markers of exposure, 33
- atmospheric vs. biological markers of absorption, 201
- bioassays needed to determine genotoxicity, 252
- biochemical markers of exposure during experimental and natural conditions, 206-207
- biological markers for absorption, 200-206
- biological markers for estimating exposure, 141
- brain cancer risk relationship, 102, 104
- cancers other than lung cancer, risk relationship, 102-104
- carbon monoxide as biological marker of exposure, 201-202
- carcinogen levels vs. mainstream smoke, 134-135, 137
- carcinogenicity, 10
- carcinogenicity, in vivo and in vitro experimental determination, 247-251

INDEX

ENVIRONMENTAL TOBACCO

SMOKE—Contd.

- cardiovascular disease risk, prospective and case-control studies, 105-106
- chemical analysis shows spectrum of carcinogens, 251-252
- chemical composition, comparison with mainstream smoke, 135, 137
- chemical composition, complexity as factor in exposure determination, 147
- chronic exposure, inferred risk for respiratory epithelial changes, 240-241
- cigarettes as major source in public places, 128
- concentration determination, ventilation and other factors, 146-147, 164-165
- concentration measurement, 193
- concentrations in public transportation as factor in smoking restrictions, 278
- constituents from mainstream and sidestream smoke, 7-8
- contribution to indoor air pollution, conclusions, 169
- cotinine as biological marker of absorption, 35-36
- cotinine as exposure marker of choice in epidemiological studies, 217
- cumulative, duration, and intensity of exposure influences effects, 33
- determinants of exposure, 11-12
- disease risk estimation, value of biological markers of absorption, 200-201
- dose, product of mass in inhaled air and deposition fraction, 193
- exposure estimation, mathematical model using "cigarette equivalents", 198-200
- exposure expressed as cigarettes/day, variations in estimates, 25-26
- exposure, extrapolation of active smoking data, 23-28
- eye irritation in exposed children, 239
- eye, nose, throat, respiratory system irritation, conclusions, 252

ENVIRONMENTAL TOBACCO

SMOKE—Contd.

- genotoxic potential, use of short-term in vitro assays, 250-251
- health effects, 21-106
- health effects, methodological problems in assessment, 21-22
- health effects of exposure, summary, 13-14
- health risk determination, assessment of exposure critical, 32
- health risks of exposure, conclusions, 7, 107-108
- human exposure, factors in estimation, 139, 141-142
- "individual solution" approach to workplace smoking implies no hazard, 298
- inflammatory cell functions in smokers, inferences for exposed nonsmokers, 244-245
- irritant components, whole sidestream smoke vs. gas phase only, 236-238
- irritant effect on allergic persons, 239
- irritant effects of exposure in nonsmokers in restaurants and offices, 232
- laboratory, toxicological, human exposure, and epidemiological investigations of hazards, 22-23
- lung cancer risk, epidemiological and case-control evidence, 97-98
- lung cancer risk in exposed nonsmokers, Hong Kong case-control study, 80-81
- lung cancer risk in spouses of smokers, Louisiana case-control study, 79-80
- lung cancer risk in spouses of smokers, Scottish study, 77-78
- lung cancer risk in wives of smokers, Greek case-control study, 78-79
- lung cancer risk, need for more accurate estimates of exposure, 102
- lung cancer risk relationship, Four Hospitals case-control study, 84-86
- lung cancer risk relationship, German case-control study, 90
- lung cancer risk relationship in nonsmokers, 8-10

INDEX

ENVIRONMENTAL TOBACCO

SMOKE—Contd.

- lung cancer risk relationship, Japanese case-control study, 88-89
- lung cancer risk relationship, Los Angeles County study, 83
- lung cancer risk relationship, preliminary findings of U.S. study, 82
- lung cancer risk relationship, summary and conclusions, 96-102
- lung cancer risk relationship, Swedish case-control study, 89-90
- lung cancer risk relationship, United Kingdom case-control study, 86-88
- lung disease risk in nonsmokers as extrapolation of risk in smokers, 30-31
- lung effects, inferences from available data, 246-247
- lung function effects in nonsmokers, 60, 62
- lung function in children, more information needed on relationship, 32
- major irritants, concentrations in mainstream and sidestream smoke (table), 230
- mass deposition in respiratory tract estimation, 193, 198
- mathematical models of lung cancer risk in nonsmokers, 93-96
- measureable exposure in general population of developed countries, 216
- misclassification of smoking status and exposure as factor in determining risk, 66-67, 72-73
- monitoring methods to estimate exposure, 164-167
- nasal vs. mouth inhalation, effect on particle deposition, 189
- nicotine and cotinine in body fluids increase with increasing exposure, 15
- nicotine and cotinine to quantify exposure, 208, 215
- nicotine as biological marker of exposure, 202-205
- nicotine as tracer, need for proper validation in personal monitoring, 168

ENVIRONMENTAL TOBACCO

SMOKE—Contd.

- nicotine levels in nonsmokers may underestimate exposure to other components, 216
- organic gases and aromatic compounds as indicators of exposure, nonspecificity, 168-169
- particle size as factor in dispersion, 169
- particle size distribution and breathing pattern effect on dose, 25
- particle size facilitates rapid distribution, 14
- particles, number and size distribution, 137, 139
- particulates, aldehydes, phenol, ammonia, and other irritants, 229
- personal monitors to measure concentrations preferable to area monitoring, 166
- physicochemical nature, distribution, and estimation of human exposure, 125-169
- plasma and urine nicotine levels in nonsmokers vs. intravenous nicotine injection, 215
- plasma, urine, saliva cotinine in exposed nonsmokers vs. active smokers (table), 211-214
- plasma, urine, saliva nicotine in exposed nonsmokers vs. active smokers (table), 209-210
- proximity to smoke source as exposure factor, 141
- questionnaires for estimating exposure, uses and limitations, 34-35
- radioactivity, 134
- reduction of exposure as primary goal of smoking regulation in public places, 304
- respirable suspended particulates in exposed vs. nonexposed nonsmokers, 169
- respiratory disease risk relationship in infants, children, adults, 10
- respiratory infections in infants, risk relationship, 31
- respiratory symptoms in nonsmokers, possible relationship, 31
- school smoking regulations traditionally not to reduce exposure, 282

INDEX

ENVIRONMENTAL TOBACCO

SMOKE—Contd.

- sidestream smoke as major contributor, 186
- statistical significance testing of health risks, 36-37
- summary and conclusions of 1986 report, 12-13
- temporal and spatial distribution of smokers in exposure determination, 145-146
- thiocyanates as biological marker of exposure, 202-203
- time-activity patterns as determinant of exposure, 142-145
- time period most important determinant of personal exposure, 167
- total suspended particulates in indoor working and living areas (table), 194-196
- toxic and carcinogenic agents indoors from nonfilter cigarettes (table), 136
- toxicity, acute irritant effects, and carcinogenicity, 15
- urinary cotinine levels in exposed vs. nonexposed men, 207
- vapor phase, retention by involuntary smokers, 126-127
- workplace exposure, evidence of health hazards as factor in smoking regulations, 286
- workplace, lung cancer risk in nonsmokers, 91-92

ENZYME ACTIVITY

- lungs of smokers, alveolar macrophages influence on protease-antiprotease balance, 242-243
- polymorphonuclear elastase in lungs of smokers, 243
- respiratory system of smoke-exposed animals, 245-246

ENZYMES

- elastase, 243

EPIDEMIOLOGICAL STUDIES

- (See also CASE-CONTROL STUDIES)
- confounding variables, 36
- lung cancer risk in spouses of smokers, 98, 101
- methodological considerations, 32-37

EPIDEMIOLOGICAL STUDIES—Contd.

- questionnaires for estimating ETS exposure, uses and limitations, 34-35

ETS See ENVIRONMENTAL TOBACCO SMOKE

EX-SMOKERS

- (See also NONSMOKERS)
- misclassification of status and ETS exposure as factors in determining risks, 66-67, 72-73

EYES

- annoying and irritating effects of ETS exposure, 231-239
- irritation from ETS exposure, 11
- irritation in ETS-exposed children, 239
- nonsmokers, irritant effect of involuntary smoking in restaurants and offices, 232
- nonsmokers, sidestream smoke as irritant in laboratory, ventilation as factor, 234-235
- smoke concentration vs. exposure duration as factors in irritation, 235
- tear film in ETS-exposed nonsmokers, experimental study, 234

FETUS

- maternal smoking, effect of exposure to tobacco smoke constituents, 31-32

GAS PHASE, CIGARETTE SMOKE

- activity in in vitro assays, 251
- irritation in nonsmokers vs. whole sidestream smoke, 236-238

HOSPITALS

- (See also PUBLIC PLACES)
- air quality, effect of smoking policies, 311
- cessation of smoking programs, effect, 314-315
- employee attitudes and approval of smoking policies, 311-312, 315
- lung cancer case-control study in four hospitals, 84-86
- smoking policies, positively worded signs and enforcement factors in compliance, 310
- smoking policies, review of current evidence on impact, 308-309

INDEX

HOSPITALS—Contd.

State legislation restricting smoking, 269

IMMUNE SYSTEM

cigarette smoking effects, 244

INFANTS

respiratory diseases, parental smoking as risk factor, 10
respiratory system effects of involuntary smoking, 38–59
time-location patterns, 144
tracheobronchial smoke particle deposition, mathematical model prediction, 192

INVOLUNTARY SMOKING

(See also ENVIRONMENTAL TOBACCO SMOKE; NONSMOKERS)

absorption vs. active smoking, 215–216
absorption of constituents under experimental and natural exposure, 206–207
adult asthmatics, lung function effects, 63, 65
allergic persons, irritant effect, 239
assessment of nonsmoker's exposure, 307
atmospheric vs. biological markers of ETS absorption in disease risk estimation, 200–201
bronchoconstriction and asthma in children of parents who smoke, 55–58
bronchoconstriction in normal adult nonsmokers, 63
cancers other than lung cancer, risk relationship, 102–104
carbon monoxide as biological marker of ETS exposure, 201–202
cardiovascular disease risk, prospective and case-control studies, 105–106
children, brain cancer risk, 104
children, lung function effects (table), 50–52
children, nonuniform deposition of particles in respiratory disease risk, 192
children, parental smoking as factor in saliva cotinine concentrations, 207–208

INVOLUNTARY SMOKING—Contd.

children, reported eye irritation, 239
children, respiratory disease relationship (table), 39–41
children, respiratory symptoms relationship (table), 45–46
children, respiratory symptoms risk, 44, 47–49
children, risk of cancer other than lung cancer, 102–104
cotinine in body fluids as measure of nicotine absorption, 205
cotinine level in saliva, blood, and urine as ETS exposure marker, 36
cumulative, duration, and intensity influences health risks, 33
disease risk estimation, value of biological markers of ETS absorption, 200–201
ETS vapor phase components, retention, 126–127
exposure to sidestream and mainstream smoke components, 8
eye and nasal irritation, smoke concentration vs. duration as factors, 235
health effects and public attitudes as factors in smoking restrictions, 265
health hazards, increasing evidence as factor in regulation, 282, 286
health risks, 6–7, 107–108
infants and children, bronchitis and pneumonia risk, 38, 42–44
infants and children, respiratory system effects, 38–59
inflammatory cell numbers and functions in smokers, inferences, 244–245
irritant effects in nonsmokers in restaurants and offices, 232
irritation from gas phase vs. whole sidestream smoke, 236–238
lung cancer dose-response relationship, problems in exposure determination, 92–93
lung cancer in spouses of smokers, prospective and case-control studies (table), 71
lung cancer in wives of smokers. Japanese prospective study, 73–76

INDEX

- INVOLUNTARY SMOKING—Contd.**
- lung cancer relationship, relative risk, 72
 - lung cancer risk, American Cancer Society Cohort Study, 76-77
 - lung cancer risk assessment, importance of definition of exposure, 92
 - lung cancer risk, bias in case-control studies (table), 98
 - lung cancer risk, epidemiological evidence, 97-98
 - lung cancer risk, evidence from case-control studies, 97
 - lung cancer risk factor in children, 90-91
 - lung cancer risk factor in non-smokers, 13
 - lung cancer risk in nonsmokers, Hong Kong case-control studies, 80-81
 - lung cancer risk in spouses of smokers, Louisiana case-control study, 79-80
 - lung cancer risk in spouses of smokers, Scottish study, 77-78
 - lung cancer risk in wives of smokers, Greek case-control study, 78-79
 - lung cancer risk relationship, case-control studies (table), 68-70
 - lung cancer risk relationship, Los Angeles County study, 83
 - lung cancer risk relationship, preliminary findings of U.S. study, 82
 - lung cancer risk relationship, prospective studies (table), 67
 - lung cancer risk relationship, summary and conclusions, 96-102
 - lung cancer risk relationship, the Four Hospitals case-control study, 84-86
 - lung cancer risk relationship, the German case-control study, 90
 - lung cancer risk relationship, the Japanese case-control study, 88-89
 - lung cancer risk relationship, the Swedish case-control study, 89-90
 - lung cancer risk relationship, the United Kingdom case-control study, 86-88
- INVOLUNTARY SMOKING—Contd.**
- lung cancer risk, study power of case-control studies (table), 99-100
 - lung disease risk, extrapolation from risk in smokers, 30-31
 - lung function effects in adult non-smokers, 60, 62
 - lung function effects in adults (table), 61
 - lung function effects in healthy adults (table), 64
 - mathematical models of lung cancer risk, 93-96
 - middle ear effusions and diseases in children, risk relationship, 58-59
 - misclassification of smoking status and exposure as factors in determining risk, 66-67, 72-73
 - nicotine and cotinine levels as exposure markers under real-life conditions, 207
 - nicotine and cotinine to quantify ETS exposure, 208, 215
 - organization of the 1986 Report, 5
 - personal monitoring to measure exposure, 33-34
 - personal monitors to measure ETS concentrations, 164-167
 - public and workplace smoking restrictions, conclusions of 1986 report, 324
 - public awareness of health hazards as factor in changing attitudes, 320
 - quantitative and qualitative differences in exposure from active smoking, 23-24
 - questionnaires for estimating exposure, uses and limitations, 34-35
 - research recommendations, 321-323
 - respirable suspended particulate levels as marker of smoke exposure, 8
 - respiratory system effects in children, case-control studies, 43-44
 - respiratory system effects in children, cross-sectional studies, 43
 - respiratory system effects in infants and children, longitudinal studies, 38, 42-43
 - State legislation in 1970s aimed at protecting nonsmokers, 267

INDEX

INVOLUNTARY SMOKING—Contd.
summary and conclusions of 1986 report, 12-13
thiocyanate levels not specific for exposure, 203
toxicity, mathematical model for estimating using "cigarette equivalents", 198-200
urinary nicotine and expired carbon monoxide in nonsmokers following exposure, 207
workplace, lung cancer risk relationship, 91-92
workplaces, current status of smoking regulations, 285-303

IRRITATION

(See also RESPIRATORY SYMPTOMS)

acute effects of ETS exposure, 229-239
allergic persons, ETS exposure effect, 239
annoying and irritating effects of ETS, 231-239
children exposed to ETS, 239
ETS exposure effects, conclusions, 252
nonsmokers, experimental studies of ETS exposure effects, 233-239

LABORATORY SMOKING

chemical analysis of sidestream smoke in special chambers, 127-129, 132
mainstream and sidestream composition data collection, 125
mainstream smoke particle size distribution (table), 184-185
particle size of mainstream smoke aerosol, measurement, 182-183, 186
sidestream smoke particle size distribution (table), 186

LEGISLATION

(See also SMOKING REGULATIONS)

average restrictiveness of State laws, 1960-1985 (figure), 276
comprehensiveness index of State laws, 327-328
current State smoking regulations, variations, 268-270
early restrictions as moral crusade and fire protection, 266-267

LEGISLATION—Contd.

emphasis shift and increase in State legislation during the 1970s, 267
Federal, State, and local to restrict smoking, 266-278
impact on smoking behavior, assessment, 306-307
local, California's nonsmokers' rights movement as factor, 277
Minnesota, landmark Clean Indoor Air Act of 1975, model for other States, 267
nonsmoking sections in restaurants mandated by State laws, 280
rate of new State legislation continues into 1980s, 268
regional variation in State laws against smoking (table), 277
restrictions and bans on smoking, 16
review of impact on smoking behavior, 320-321
smoking regulations, conclusions of 1986 report, 324
social norms and public attitudes as factors in passage, 321
State and local laws and Federal regulation in health care facilities, 284-285
State and local laws on public smoking, influence on private sector, 295
State and local smoking control statutes, implementation evaluation, 316-318
State, increase in comprehensiveness of smoking regulations since 1970, 275
State laws regulating smoking in public places and workplaces (table), 271-274
State laws restricting smoking, 1970-1985 (table), 269
States with no regulations against smoking, 268
student smoking, legal incentive for regulation by schools, 282
tobacco-producing States have less restrictive laws on smoking, 275-276
workplace smoking, early controversy, 286

INDEX

LEGISLATION—Contd.

- workplace smoking, private sector, State and local laws, 285
- workplace smoking, regulation, variations in State laws, 270, 275

LEUKEMIA

- children of women who smoked during pregnancy, risk relationship, 103-104

LEUKOCYTES

- polymorphonuclear, lung disease risk relationship in smokers, 243-244

LUNG CANCER

(See also **CANCER**)

- animals exposed to cigarette smoke, 248-249
- confounding variables in studies of ETS risk in nonsmokers, 36
- ETS as risk factor in nonsmokers, 8-10
- ETS exposure as risk in nonsmokers, Hong Kong case-control studies, 80-81
- ETS risk relationship, need for more accurate estimates of exposure, 102
- involuntary smokers, study power of case-control studies (table), 99-100
- involuntary smoking as factor, American Cancer Society Cohort Study, 76-77
- involuntary smoking as factor, Los Angeles County study, 83
- involuntary smoking as factor, preliminary findings of U.S. study, 82
- involuntary smoking as factor, relative risk, 72
- involuntary smoking as factor, the Four Hospitals case-control study, 84-86
- involuntary smoking as factor, the German case-control study, 90
- involuntary smoking as factor, the Japanese case-control study, 88-89
- involuntary smoking as factor, the Swedish case-control study, 89-90

LUNG CANCER—Contd.

- involuntary smoking as factor, the United Kingdom case-control study, 86-88
- involuntary smoking as risk factor, bias in case-control studies (table), 98
- involuntary smoking as risk factor, case-control studies (table), 68-70
- involuntary smoking as risk factor, prospective studies (table), 67
- involuntary smoking as risk factor, summary and conclusions, 96-102, 107
- involuntary smoking dose-response relationship, problems in exposure determination, 92-93
- mathematical models of ETS exposure risk in nonsmokers, 93-96
- methodological issues in assessing involuntary smoking risk, 66-67, 72-73
- mortality in nonsmoking wives of smokers, 27
- nonsmokers, case-control study evidence of ETS exposure as risk factor, 97
- nonsmokers, epidemiological evidence of ETS exposure as risk factor, 97-98
- nonsmokers, involuntary smoking as risk factor, 13, 66-101
- nonsmokers, projection of ETS risk from relationship with smoking in smokers, 26-27
- nonsmoking spouses of smokers, Louisiana case-control study, 79-80
- nonsmoking spouses of smokers, potential bias in Japanese study, 74-75
- nonsmoking spouses of smokers, Scottish study, 77-78
- nonsmoking wives of smokers, Japanese prospective study, 73-76
- nonuniform carcinogenic particle deposition as possible risk factor, 192
- parental smoking as risk factor, 90-91
- sample size of concern in studies of nonsmokers, 22
- smoking as major risk factor, 6

INDEX

LUNG CANCER—Contd.

- spousal smoking as risk factor, prospective and case-control studies (table), 71
- women married to smokers, Greek case-control study, 78-79

LUNG DISEASES

(See also RESPIRATORY TRACT DISEASES)

- active smokers, extrapolation of risk in involuntary smokers, 30
- bronchiolitis, early pathologic lesions in smokers, 241

LUNG FUNCTION

- adult asthmatic nonsmokers exposed to cigarette smoke, 63, 65
- adults exposed to involuntary smoking (table), 61
- asymptomatic adults, long-term workplace exposure as risk factor, 60
- children and adolescents who start to smoke, 28
- children and adults, conclusions about ETS exposure risk, 107
- children, information needed on relationship with ETS exposure, 32
- children, involuntary smoking risk relationship (table), 50-52
- children, maternal smoking relationship, 49, 53-54
- healthy nonsmokers exposed to cigarette smoke (table), 64
- nonsmokers, ETS as factor in decline, 10
- nonsmokers, extrapolation of ETS risk from risks in smokers, 27

LUNGS

- (See also RESPIRATORY SYSTEM)
- carbon monoxide deposition kinetics as factor in variations in concentration, 201-202
 - children of parents who smoke, possible long-term effects, 44
 - cigarette smoking effect, implications for chronic ETS exposure, 239
 - cigarette smoking effects, summary, 246-247
 - inflammatory cell function, experimental models of cigarette smoke inhalation, 245-246

LUNGS—Contd.

- inflammatory cells, cigarette smoking effect, 241-246
- inflammatory lesions in smokers vs. nonsmokers, 245
- parenchyma alterations in smokers, 246
- parenchyma destruction by polymorphonuclear elastase in smokers, 243
- regional deposition of mainstream smoke particles in smokers, 189, 191
- respirable particle deposition, non-uniformity, 191-192
- sidestream smoke particle deposition, mass median diameter as factor, 187

MAINSTREAM SMOKE

- (See also CIGARETTE SMOKE; SIDESTREAM SMOKE; SMOKE STREAMS; TOBACCO SMOKE)
- condensates, in vitro assays of mutagenic activity, 250-251
 - definition, 7
 - electrical charge as factor in particle deposition, 187
 - particle size distribution studies, 140
 - particle size distribution (table), 184-185
 - regional deposition in respiratory tract of smokers, 189, 191
 - respiratory system deposition vs. sidestream smoke (table), 190

MATERNAL SMOKING

- (See also PARENTAL SMOKING)
- asthmatic children, risk relationship, 55-58
 - brain tumors in children, risk relationship, 104
 - cancer other than lung cancer in children, risk relationship, 103-104
 - health risks for fetus and neonate, 6
 - leukemia in children of women who smoked during pregnancy, 103
 - lung function in children, risk relationship, 49, 53-54
 - lung function in children, risk relationship (table), 50-52

INDEX

MATERNAL SMOKING—Contd.

- respiratory illness in children, case-control studies of risk, 43-44
- respiratory illness in children, cross-sectional studies of risk, 43
- respiratory illness in infants and children, 38, 42-43

MATHEMATICAL MODELS

- airways deposition of sidestream smoke suggested, 217
- humidity effect on particle size and deposition, 187-188
- lung cancer risk of ETS exposure, 93-96
- particle deposition patterns, effect of cigarette tar content, 191
- regional deposition of polydisperse aerosols, 189
- respirable suspended particulate constituent of ETS for exposure prediction, 165
- respiratory tract deposition of sidestream smoke particles, 186-187
- tracheobronchial smoke particle deposition prediction, age as factor, 192

MINNESOTA

- landmark Clean Indoor Air Act, model for other States, 267
- public approval of 1975 Clean Indoor Air Act, 318-319

MORTALITY

- cancers other than lung cancer, standard ratios for wives of smokers, 102
- lung cancer, establishing risk in nonsmokers, 95-97
- lung cancer in ETS exposed nonsmokers, American Cancer Society Cohort Study, 76-77
- lung cancer in nonsmoking wives of smokers, 27
- lung cancer in spouses of smokers, Scottish study, 77-78
- lung cancer in wives of smokers, Japanese prospective study, 73-76
- maternal smoking as risk factor for infant mortality, 6

MOTIVATION

- cessation of smoking, public attitudes and restrictions as reinforcement, 305
- worker safety not health as factor in early smoking regulations, 287
- workplace smoking policies, effect on smoking cessation attempts, 313-314
- workplace smoking regulation, 295-296

NICOTINE

- (*See also* TOBACCO SMOKE CONSTITUENTS)
- absorption in nonsmokers to assess lung cancer risk, 9
- absorption in populations suggests ETS exposure is common, 15
- acute toxicity in animals as factor in smoke carcinogenicity testing, 247
- atmospheric levels as marker of ETS exposure, 33
- biological fluid levels, promising tracer of ETS exposure, 165-166
- blood levels, metabolism, and excretion rate to determine intake, 203-204
- body fluid levels as marker of smoke exposure in nonsmokers, 8
- body fluid levels increase with reported ETS exposure, 15, 217
- body fluid levels specificity for tobacco or tobacco smoke exposure, 204
- ETS as source in general environment, 14, 169
- ETS exposure determination, specificity, 147
- ETS exposure quantification, 208, 215
- ETS tracer, need for proper validation, 168
- measurement under realistic conditions (table), 155-156
- personal air monitoring for intake determination, 216
- plasma and urine levels from intravenous infusion vs. ETS exposure in nonsmokers, 215

INDEX

NICOTINE—Contd.

- plasma, urine, saliva levels in non-smokers vs. active smokers, 209-210, 216
- suspended particulate levels as measurement of ETS exposure, 193
- tobacco smoke exposure determination, absorption, distribution, metabolism, 203-205
- vapor phase of sidestream vs. mainstream smoke, 127

NITROGEN OXIDES

- carcinogenic potential of oxides of nitrogen in sidestream smoke, 129
- irritant in ETS, 229
- measurement under realistic conditions (table), 157
- nitrogen dioxide in sidestream smoke, carcinogenic potential, 129

NITROSAMINE CONTENT

- N-nitrosamines in sidestream vs. mainstream smoke, 129

NITROSAMINES

- ETS as only source of some N-nitrosamine compounds in general environment, 169
- ETS exposure determination, specificity, 147
- measurement under realistic conditions (table), 158
- sidestream smoke levels higher than in mainstream smoke, 14

NONSMOKERS

- absorption of smoke constituents under experimental and natural exposure, 206-207
- blood cotinine levels, nicotine injection vs. smoke exposure, 215-216
- California nonsmokers' rights movement as factor in local smoking regulation, 277
- cardiovascular disease, prospective and case-control studies of ETS risk, 105-106
- chronic ETS exposure, inferred risk for respiratory epithelium, 240-241
- cotinine elimination half-life vs. smokers, 205-206

NONSMOKERS—Contd.

- emphysema risk vs. smokers, genetic predisposition as factor, 246
- ETS as lung cancer risk factor, problems in exposure determination, 92-93
- ETS-exposed, plasma, urine, saliva cotinine vs. active smokers (table), 211-214
- ETS-exposed, plasma, urine, saliva nicotine vs. active smokers (table), 209-210
- ETS exposure, experimental studies of irritant effects, 233-239
- ETS exposure, relationships with active smoking provide insight into risks, 26-28
- ETS exposure toxicity, mathematical model using "cigarette equivalents", 198-200
- ETS exposure, wide variations, 14
- health risks of ETS exposure, conclusions, 107-108
- health risks of involuntary smoking, summary and conclusions, 12-13
- irritant effects of involuntary smoking in restaurants and offices, 232
- irritation from sidestream smoke vs. gas phase sidestream smoke, 236-238
- irritation from smoke exposure, concentration vs. duration as factors, 235
- lung cancer, establishing risk of ETS exposure, 95
- lung cancer, ETS exposure as factor, Four Hospitals case-control study, 84-86
- lung cancer, ETS exposure as factor, German case-control study, 90
- lung cancer, ETS exposure as factor, Hong Kong case-control study, 80-81
- lung cancer, ETS exposure as factor, Japanese case-control study, 88-89
- lung cancer, ETS exposure as factor, Los Angeles County study, 83

INDEX

NONSMOKERS—Contd.

- lung cancer, ETS exposure as factor, preliminary findings of U.S. study, 82
- lung cancer, ETS exposure as factor, Swedish case-control study, 89-90
- lung cancer, ETS exposure as factor, United Kingdom case-control study, 86-88
- lung cancer in spouses of smokers, prospective and case-control studies (table), 71
- lung cancer, involuntary smoking as risk factor, 13
- lung cancer risk from ETS exposure, 8-10
- lung cancer risk from ETS as projection of relationship of smoking in smokers, 26-27
- lung cancer risk in spouses of smokers, Japanese prospective study, 73-76
- lung cancer risk in spouses of smokers, Louisiana case-control study, 79-80
- lung cancer risk in spouses of smokers, Scottish study, 77-78
- lung cancer risk of ETS exposure, American Cancer Society Cohort Study, 76-77
- lung cancer risk of involuntary smoking, case-control studies (table), 68-70
- lung cancer risk of involuntary smoking, more accurate data needed, 102
- lung function in healthy adults exposed to cigarette smoke (table), 64
- mathematical models of lung cancer risk with ETS exposure, 93-96
- misclassification of status and ETS exposure as factors in determining risk, 66-67, 72-73
- nicotine and cotinine to quantify ETS exposure, 208, 215
- odor perception and irritation, influence of room temperature and humidity, 234
- plasma and urine nicotine levels, intravenous vs. ETS exposure effect, 215

NONSMOKERS—Contd.

- plasma, saliva, and urine nicotine and cotinine levels vs. active smokers, 216
- preferential hiring, most restrictive smoking policy, 301-302
- private, local, governmental actions for protection from smoke exposure, 265
- respirable suspended particulates in ETS-exposed vs. nonexposed, 169
- review of impact of smoking restrictions on attitudes, 320
- separation from smokers for risk reduction, effectiveness, 11-12
- State antismoking legislation in 1970s aimed at protection, 267
- temporal and spatial distribution of smokers in ETS exposure determination, 145-146
- urinary cotinine levels in ETS-exposed vs. nonexposed men, 207
- urinary nicotine and expired carbon monoxide, effects of smoke exposure, 207
- workplace bans for maximum protection, momentum growing among large employers, 301
- workplace demands for clean air as motivation for smoking regulations, 296
- workplace smoking as eye irritant, 233
- workplace smoking as lung cancer risk factor, 91-92

NOSE

- annoying and irritating effects of ETS exposure, 231, 235
- ETS particle deposition, effect of nasal inhalation, 189
- smoke concentration vs. exposure duration as factors in irritation, 235

PARENTAL SMOKING

- (See also **MATERNAL SMOKING**)
- cancers other than lung cancer in children, risk relationship, 102-105
- cough, phlegm, and wheezing in children, 44, 47-49
- lung cancer risk relationship, 90-91
- lung function in children, relationship (table), 50-52

INDEX

PARENTAL SMOKING—Contd.

- lung function in children, risk relationship, 53-54
- middle ear effusions and diseases in children, risk relationship, 58-59
- respiratory illness in infants and children, 38, 42-44
- respiratory symptoms in children, 13
- respiratory symptoms in children, relationship (table), 45-46
- respiratory system effects in children, 38-59
- saliva cotinine concentrations in children, effect, 207-208

Passive Smoking See INVOLUNTARY SMOKING

PHYSICAL ACTIVITY

- ETS deposition increase with increasing activity, 187

PREGNANCY

- fetal exposure to tobacco smoke constituents, possible effects, 31-32
- leukemia risk in children of smokers, 103

PUBLIC PLACES

(See also HOSPITALS; WORK-PLACE)

- current status of smoking regulations mix of public and private actions, 265-266
- employee attitudes before smoking policy implementation, 311
- health care facilities, public support of smoking restrictions, 284
- health care facilities, smoking regulations, 283-285
- hotels and motels, smoking regulations, 281-282
- impact of public and workplace policies restricting smoking, 303-321
- interstate transportation, smoking regulated at Federal level, 278
- legislation restricting smoking, evaluation of impact, 316-318
- local smoking regulations, 277-278
- public transportation, smoking regulations, 278-279

PUBLIC PLACES—Contd.

- research recommendations on effects of smoking regulations, 321
- restaurants, opposition, acceptance, and implementation of smoking restrictions, 280
- restaurants, smoking regulations, 279-281
- retail stores, smoking regulations, 279
- schools, smoking regulations, 282-283
- smoking regulation, State laws (table), 271-274
- smoking regulations, conclusions of 1986 report, 324
- smoking regulations, factors in acceptability, 266
- smoking regulations in specific public places, 278-285
- smoking regulations, public approval, national and regional polls, 318-319
- smoking restrictions, variations in current State legislation, 268-270
- State laws regulating smoking, comprehensiveness index, 327-328
- State legislation to restrict smoking, increase during the 1970s, 267
- States restrict smoking in transportation, hospitals, elevators, and others, 269
- total suspended particulates (table), 194-195

PULMONARY ALVEOLAR MACROPHAGES

- lung injury relationship in smokers, 241-243, 245
- protease-antiprotease balance in lungs of smokers, influence, 242-243
- respiratory bronchioles of smoke-exposed animals, 245-246

PYRIDINES

- sidestream vs. mainstream smoke levels, 129

RADIATION

- decay products of radon in tobacco smoke, 132, 134
- ETS radioactivity, 134

INDEX

REDUCTION OF SMOKING

(See also CESSATION OF SMOKING)
public attitudes and smoking policies as indirect influences, 304-305

RESIDENCES

total suspended particulates (table), 195-196

RESPIRABLE SUSPENDED PARTICULATES

enclosed places, ETS role, 169
ETS-exposed and nonexposed samples, percentage distribution, 167
hospital before and after adopting restrictive smoking policy, 311
irritants in ETS, 229
marker for ETS exposure, 33-34
personal monitors to measure ETS exposure, 166-168
residential levels as function of number of smokers (table), 164
respiratory disease risk in children of smokers, 192
tracheobronchial deposition in infants vs. adults, prediction, 192

RESPIRATORY FUNCTION TESTS

children, involuntary smoking as risk factor, 53-54
nonsmokers exposed to involuntary smoking, 62-63
predicted levels, relationship with number of cigarettes smoked, 29

RESPIRATORY SYMPTOMS

(See also COUGH; IRRITATION; NOSE)
annoying and irritating effect of ETS exposure, 231-232, 238-239
children and adolescents who start to smoke, 27
children and adults, ETS exposure as factor, conclusions, 107
children, parental smoking as factor, 13
children, relationship with involuntary smoke exposure (table), 45-46
cough, phlegm, and wheezing in adults, ETS exposure as risk not established, 60

RESPIRATORY SYMPTOMS—Contd.

cough, phlegm, wheezing in children, parental smoking as factor, 44, 47-49
involuntary smokers, 31

RESPIRATORY SYSTEM

(See also LUNGS)
animals, carcinogenicity of cigarette smoke, 247-248
breathing pattern and particle size distribution effect on ETS dose, 25
breathing patterns as factor in sidestream smoke deposition, 187
bronchoconstriction in children, parental smoking as risk factor, 55-58
bronchoconstriction in normal adults exposed to involuntary smoking, 63
cigarette smoking effects, implications for involuntary smoking risks, 239-241
deposition and absorption of tobacco smoke constituents, 181-216
deposition of mainstream and sidestream smoke, 25
enzyme activity in smoke-exposed animals, 245
epithelial cells, dose-response effect of cigarette smoking, 239
ETS deposition, 193-216
ETS dose, product of mass in inhaled air and deposition fraction, 193
hyperplasia and metaplasia in trachea and bronchi of smoke-exposed animals, 248
involuntary smoking effects, 37-65
mass deposition of ETS, estimation, 193
nasal vs. mouth inhalation of ETS, effect on particle deposition, 189
nose, throat, and airway irritation from smoke exposure, 11
particle size of cigarette smoke as factor in deposition, 182
puffing and inhalation patterns as factor in particle deposition, 183
regional deposition of smoke particles, 189, 191
sidestream and mainstream smoke deposition (table), 190

INDEX

RESPIRATORY SYSTEM—Contd.

- sidestream smoke particle deposition, 186-189
- smoke particle size as factor in regional deposition, 189, 191-192

RESPIRATORY TRACT CANCER

- animals exposed to cigarette smoke, 248

RESPIRATORY TRACT DISEASES

- acute illness in children, parental smoking as risk factor, 38, 42-44
- asthma in children, maternal smoking as risk factor, 55-58
- children, case-control studies of paternal smoking as risk factor, 43-44
- children, nonuniform deposition of smoke particles as risk factor, 192
- children, parental smoking as factor, 13
- children, parental smoking as risk factor, 38-59
- early childhood, involuntary smoking relationship (table), 39-41
- involuntary smoking as risk factor, 10
- nonsmoking adults and children, involuntary smoking as factor, 37-66
- pneumonia in children of smokers, conclusions about risk, 107
- population characteristics as factor in ETS risk, 28
- smoking as major risk factor, 6

RESPIRATORY TRACT INFECTIONS

- children of smokers, conclusions about risk, 107
- infants, ETS exposure as risk factor, 31

SALIVA

- cotinine level as marker for ETS exposure in nonsmokers, 36
- cotinine levels in ETS-exposed nonsmokers vs. active smokers (table), 211-214
- nicotine and cotinine levels to quantify ETS exposure, 208, 215
- nicotine levels as sidestream smoke exposure indicator, 204-205

SALIVA—Contd.

- nicotine levels in ETS-exposed nonsmokers vs. active smokers (table), 209-210
- nicotine levels in nonsmokers vs. smokers, 216

SIDESTREAM SMOKE

(See also CIGARETTE SMOKE;

MAINSTREAM SMOKE;
SMOKE STREAMS; TOBACCO
SMOKE)

- bioassays needed to determine genotoxicity, 252
- carbon monoxide and carbon dioxide levels vs. mainstream smoke, 129
- carcinogen levels vs. mainstream smoke, 24
- carcinogenic potential, effect of levels of oxides of nitrogen, 129
- carcinogenicity vs. mainstream smoke in animal models, 252
- chemical analysis, 127-129, 132
- chemical composition as factor in estimating exposure using "cigarette equivalents", 199
- component levels, combustion temperature effect vs. mainstream smoke, 128-129
- constituent formation vs. mainstream smoke, 7-8
- definition, 7
- experimental and mathematical models show deposition in airways, 217
- formaldehyde and acrolein concentrations above occupational limits, 230
- formation and physiochemical nature, 127
- inhalation effects in laboratory animals not reported, toxicity factor, 249
- irritation in nonsmokers vs. gas phase sidestream smoke vs. acrolein, 236-237
- irritation of nonsmokers in laboratory, ventilation as factor, 234-235
- laboratory collection devices, 125-126
- major source of ETS, 125

INDEX

SIDESTREAM SMOKE—Contd.

- mass median diameter, effect on deposition in respiratory tract, 187
- mathematical models of particle deposition in respiratory tract, 186-187
- nicotine in vapor phase vs. mainstream smoke, 127
- particle distribution in respiratory tract, 186-189
- particle size distribution studies (table), 138
- particle size distribution (table), 186
- particles, number and size distribution, 137, 139
- particulate matter vs. mainstream smoke, 129, 132
- particulate phase as major determinant of irritation in nonsmokers, 237-238
- physicochemical nature and spectrum of carcinogens, summary, 251-252
- regional deposition in respiratory tract, particle size as factor, 189, 191-192
- respiratory system deposition vs. mainstream smoke (table), 190
- saliva nicotine levels as indicator of exposure, 204-205
- toxic and carcinogenic agents, 21
- toxic and carcinogenic compounds, 14
- toxic and carcinogenic compounds vs. mainstream smoke, conclusions, 169
- tumor induction by condensate on mouse skin vs. mainstream smoke condensate, 250
- vapor and particulate phase constituents, sidestream to mainstream ratio (table), 130-131

SMOKE INHALATION, ANIMAL

- carcinogenicity testing, 247-250
- laryngeal leukoplakias in hamsters, 248-249
- lung and respiratory cancers in mice and rats, 248
- lung inflammatory cell function, experimental models, 245-246

SMOKE STREAMS

(See also CIGARETTE SMOKE; MAINSTREAM SMOKE; SIDESTREAM SMOKE; TOBACCO SMOKE)

- combustion temperature effect on components of sidestream vs. mainstream smoke, 128-129
- mainstream and sidestream smoke, comparison, 23-25
- mainstream smoke vs. ETS, chemical composition, 135, 137
- mainstream vs. sidestream smoke from unfiltered cigarette, comparison (table), 128
- particulate matter in mainstream and sidestream smoke, 129, 132
- sidestream and mainstream smoke inhalation by smokers and involuntary smokers, 126-127
- toxic and carcinogenic agents in indoor mainstream vs. ETS (table), 136
- vapor and particulate phase constituents, sidestream to mainstream ratio (table), 130-131

SMOKING

- immune system effects, 244
- public knowledge and attitudes, policy impact assessment by surveys, 307
- public places and workplaces, State regulations (table), 271-274
- regulatory approaches of State and local governments, 278

SMOKING CHARACTERISTICS

- compensatory smoking by workers following smoking policy implementation, 312-313
- machine smoking simulation, inconsistency with current patterns, 126-127
- puffing and inhalation effect on particle deposition, vs. machine smoking, 183

SMOKING CONTROL PROGRAMS

- evaluation, methodological considerations, study design as factor, 306-308
- guides on how to adopt and implement regulatory policies, 302

INDEX

SMOKING CONTROL

PROGRAMS—Contd.

- "individual solution" approach to control workplace smoking, 298
- separating smokers and nonsmokers, improving workplace ventilation, 299
- workplace cessation of smoking programs as part of control policies, 297
- workplace restrictions on where smoking is allowed, variations, 299-300

SMOKING HABIT

- consumption decline, effect of public attitudes and social norms, 321
- population group differences in ETS exposure determination, 145-146
- research recommendations on effect of smoking restrictions, 322
- smoking restrictions with most impact on behavior, research needed, 323

SMOKING MACHINES

(See also LABORATORY SMOKING)

- human smoking simulation inconsistent with current patterns, 126-127
- standard conditions for machine smoking cigarettes, 125

SMOKING REGULATIONS

(See also LEGISLATION)

- assessment of effect on air quality, 307
- average restrictiveness of State laws, 1960-1985 (figure), 276
- case-control studies of impact on human behavior, evaluation, 306
- current State legislation, variations, 268-270
- designated smoking or no-smoking areas to control workplace smoking, 299-300
- employer-mandated policies in the private sector, opposition, 296-297
- enforcement costs, experience contradicts tobacco industry estimates, 316

SMOKING REGULATIONS—Contd.

- geographic variability of State laws on smoking in public places (figure), 270
- health care facilities, 283-285
- health care facilities, public support, 284
- health care facilities, variations in policies, 284-285
- hospitals, awareness and compliance, 309-310
- hospitals, effect on air quality, 311
- hospitals, employee approval of policies, 312
- hospitals, positively worded signs and enforcement factors in compliance, 310
- hospitals, review of current evidence of impact, 308-309
- hotels and motels, private initiative in response to perceived demand, 281-282
- hotels and motels, public support, 281-282
- impact on air quality, behavior, attitudes, 303-321
- implementation, 309-310
- implementation, assessment of impact, 307-308
- implementation of workplace policies, 302-303
- implementation, smokers' support as factor, 303-304
- legislation to restrict smoking in public places, 266-276
- local legislative restrictions, 277-278
- local restrictions, California's nonsmokers' rights movement as factor, 277
- nonsmoker's exposure to second-hand smoke, assessment of impact, 306
- policy components that impact on smoking behavior, research needed, 323
- preferential hiring of nonsmokers as most restrictive policy, 301-302
- public and private organizations, employees' attitudes, 311-312
- public and workplace, conclusions of 1986 report, 324

INDEX

SMOKING REGULATIONS—Contd.

- public and workplace control policies, indirect effects, 304–305
- public and workplace restrictions, review of impact, 303–321
- public approval, national and regional polls, 318–319
- public awareness, compliance, and enforcement of violations in implementation, 303
- public places and workplaces, Federal, State, and local action, 15–16
- public places and workplaces, State laws (table), 271–274
- public places, current status mix of public and private actions, 265–266
- public places, factors in acceptability, 266
- public places, role of public attitudes and social norms, 321
- public support, 16
- public transportation, 278–279
- regional variation in State laws against smoking (table), 277
- research must consider policy characteristics, institution, and population, 321–323
- research recommendations, 321–323
- restaurants, 279–281
- restaurants, opposition, acceptance, and implementation, 280
- retail stores, 279
- review of impact on attitudes and social norms, 319–320
- schools, difficulties in enforcement, 283
- schools, double standard of teacher smoking vs. student restrictions, 283
- schools, traditionally not to reduce sidestream smoke exposure, 282
- social phenomenon, impact information lacking, need for research, 323
- specific public places, 278–285
- State and local governments, restrictions, 12
- State and local statutes, implementation evaluation, 316–318
- State laws, comprehensiveness index, 327–328

SMOKING REGULATIONS—Contd.

- State laws restricting smoking, 1970–1985 (table), 269
- State legislation, emphasis shift and increase during the 1970s, 267
- State legislation in 1970s aimed at protecting nonsmokers, 267
- State legislation, increase in comprehensiveness, 275
- States with no smoking legislation, 268
- tobacco-producing States, fewer enacted and less restrictive, 275–276
- worker safety as motivation for early policies, 287
- workplace ban, complexity of assuring compliance, 301–302
- workplace bans, usually preceded by progressively stricter regulations, 300–301
- workplace, barriers to adopting policies, 296–297
- workplace, categories of policies, 298
- workplace compliance with local ordinances, type of business as factor, 317
- workplace, current evidence of impact, 308–309
- workplace, current status, 285–303
- workplace, early controversy in the private sector, 286
- workplace, economic considerations apparently not a factor, 296
- workplace, effect on smoking cessation motivation and success, 313–315
- workplace, employee attitudes before policy implementation, 311
- workplace, impact on absenteeism, health care costs, productivity, turnover, 315–316
- workplace, impact on health care and maintenance costs, 305
- workplace, influence of nonsmokers' demand for clean air, 286
- workplace, nature, scope, and prevalence in the 1980s, 294–295
- workplace, policy implementation effect on smokers' behavior, 312–313

INDEX

SMOKING REGULATIONS—Contd.

- workplace, prevalence, 286–287, 294–295
- workplace, public vs. private sector, 270
- workplace, worker health, State legislation, nonsmokers' demands as factors, 295–296
- workplace, workforce size, industry type, geographic location as factors, 295
- workplaces, survey data 1977–1986 (table), 288–293

SMOKING STATUS

(See also SMOKING HABIT)

- misclassification as factor in determining ETS risk, 98, 101
- misclassification as factor in determining health risks of involuntary smoking, 66–67, 72–73

SMOKING SURVEYS

- workplaces, 287, 294–295

STATISTICS

- significance testing of ETS risks, 36–37

TARS, CIGARETTE

- carcinogenicity testing in animals, 247–248
- chemical assay for human exposure to components, research goal, 217
- tumor induction on mouse skin, sidestream vs. mainstream condensates, 250

TARS, TOBACCO

- particulates measured under realistic conditions (table), 159–162
- sidestream smoke particle size distribution studies (table), 138

THIOCYANATES

- sources, metabolism, elimination, half-life, 202–203

TOBACCO SMOKE

- (See also CIGARETTE SMOKE; MAINSTREAM SMOKE; SIDESTREAM SMOKE; SMOKE STREAMS)
- absorption during active smoking vs. involuntary smoking, 215–216

TOBACCO SMOKE—Contd.

- biological markers of smoke absorption in smokers and nonsmokers, 181
- machine vs. human smoking, non-comparability of chemical and physiochemical data, 135
- mainstream vs. environmental, characteristics, 6
- nicotine in vapor phase, sidestream vs. mainstream, 127
- odor perception and irritation, influence of room temperature and humidity, 234
- particle size distribution of mainstream smoke (table), 184–185
- particle size distribution of sidestream smoke (table), 186
- quantitatively determined compounds in sidestream and mainstream smoke, 128
- radioactivity, 132, 134
- residuals, measured under realistic conditions (table), 163
- vapor phase, retention by smokers vs. involuntary smokers, 126–127
- workplace air pollution, contribution (table), 233

TOBACCO SMOKE CONSTITUENTS

(See also COTININE; NICOTINE)

- absorption in nonsmokers under experimental and natural exposures, 206–207
- chemical assay for human exposure to tar components, research goal, 217
- deposition and absorption, 181–216
- deposition fraction of individual components needed to determine disease risk, 200
- ETS and mainstream differences as factor in exposure of nonsmokers vs. smokers, 201
- ETS exposure quantification, 208, 215
- irritants also produced by other sources, 229–230
- irritants in ETS, 229
- nicotine, absorption, distribution, metabolism, and body fluid levels, 203–205

INDEX

- TOBACCO SMOKE CONSTITUENTS—Contd.**
particle deposition in lung areas, nonuniformity, cancer risk relationship, 192
trapping devices to analyze individual components, 126
- TOBACCO SMOKE PARTICULATES**
carcinogenicity testing in animals, 247-248
indoor concentrations by cigarette smoking under laboratory conditions (table), 197
irritation in nonsmokers vs. gas phase of sidestream smoke, 237-238
potential toxicity estimation using "cigarette equivalents", deficiencies, 199
total suspended particulates in indoor working and living environments (table), 194-196
- URINE**
cotinine level as marker for ETS exposure in nonsmokers, 36
cotinine levels in ETS-exposed nonsmokers vs. active smokers (table), 211-214
cotinine levels in ETS-exposed vs. nonexposed men, 207
mutagenic activity not good measure of tar absorption, 206
nicotine and cotinine levels to quantify ETS exposure, 208, 215
nicotine excretion, individual metabolism as factor in smokers and nonsmokers, 203-205
nicotine levels in ETS-exposed nonsmokers vs. active smokers (table), 209-210
nicotine levels in nonsmokers vs. smokers, 216
- VENTILATION**
ETS components elimination, major factor, 146-147, 164-165
ETS, determinant of exposure, 11
ETS, effect on levels, 229
ETS, factor in estimating human exposure, 139, 141-142
involuntary smoking exposure, factor, 67
restaurants, inadequate control of ETS levels, 279
- VENTILATION—Contd.**
sidestream smoke in laboratory, effect on perceived irritation in nonsmokers, 234-235
- WOMEN**
cancers other than lung cancer in nonsmokers married to smokers, 102
lung cancer in wives of smokers, Greek case-control study, 78-79
lung cancer, involuntary smoking as factor, German case-control study, 90
lung cancer risk in wives of smokers, Japanese prospective study, 73-76
lung cancer risk with ETS exposure, Hong Kong case-control studies, 80-81
- WORKPLACE**
(See also PUBLIC PLACES)
barriers to adopting smoking policies, 296-297
carbon monoxide, nitrogen, and particulate matter levels due to tobacco smoke, 232
categories of smoking policies, 298
compliance with local smoking ordinances, type of business as factor, 317
health care and maintenance cost reduction as benefit of smoking policy, 305
hospitals, employee approval of smoking policies, 312
involuntary smoking, irritant effects, 232
irritants, tobacco smoke and other sources, 229-230
preferential hiring of nonsmokers as most restrictive smoking policy, 301-302
research recommendations on effect of smoking regulations, 321
safety as motivation for early regulations against smoking, 287
smoking policies, survey data 1977-1986 (table), 288-293
smoking restrictions, conclusions of 1986 report, 324
State laws regulating smoking, comprehensiveness index, 327-328

INDEX

WORKPLACE—Contd.

- surveys of smoking policies, 287, 294-295
- tobacco smoke contribution to air pollution (table), 233
- total suspended particulates (table), 194-195

WORKPLACE SMOKING

(See also ENVIRONMENTAL TOBACCO SMOKE; INVOLUNTARY SMOKING)

- bans, usually preceded by progressively stricter regulations, 300-301
- business type as factor in compliance with local smoking ordinances, 317
- cessation programs as part of private sector smoking control, 297
- control by restricting where smoking is allowed, variations, 299-300
- ETS exposure determination, factor, 142
- eye irritation reported in nonsmokers, 233
- government offices, smoking regulation increasing, 285
- guides on how to adopt and implement smoking policies, 302
- hospitals, awareness and compliance of employees, 309-310
- hospitals, review of current evidence on impact of smoking regulations, 308-309
- impact of public and workplace restrictions, 303-321

WORKPLACE SMOKING—Contd.

- "individual solution" approach to regulation, 298
- legislated restriction, early controversy, 286
- lung cancer risk factor in nonsmokers, 91-92
- lung function effects of exposure in nonsmokers, 60
- motivation for regulation, 295-296
- nature, scope, and prevalence of regulation in the 1980s, 294-295
- policy implementation effect on smokers, 312-313
- private sector regulation, legislation and public support as factors, 295
- private sector, State and local legislation, 285
- regulation, impact on absenteeism, health care costs, productivity, turnover, 315-316
- regulations, current status, 285-303
- regulations supported by smokers and nonsmokers, 285
- regulations, workforce size, geographic location, type of industry as factors, 295
- restrictions, 16
- restrictions, voluntary vs. governmental, 12
- schools, restrictions to reduce faculty/staff exposure to ETS, 282
- State regulation, public vs. private sector, 270
- State regulations (table), 271-274
- urinary cotinine levels as marker of exposure in nonsmokers, 207